Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
BackgroundConcurrent programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors with sequential chemoradiotherapy (SCRT) have been reported in only a limited number of studies involving patients with unresectable stage III non-small-cell lung cancer (NSCLC). A retrospective study was...
Main Authors: | Shi Tang, Xiaofeng Cong, Dan Zheng, Chen Chen, Zengguang Liu, Jie Gao, Huimin Zhang, Youhao Zhang, Ziling Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1129989/full |
Similar Items
-
Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022-11-01) -
A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma
by: He J, et al.
Published: (2022-08-01) -
Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report
by: Huimin Zhang, et al.
Published: (2024-02-01) -
Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review
by: Chuan Lv, et al.
Published: (2022-10-01) -
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01)